GargSK, Wernicke-PantenK, RojeskiM, PierreS, KirchheinY, and JedynastyK: Efficacy and safety of biosimilar SAR342434 insulin lispro in adults with type 1 diabetes also using insulin glargine—SORELLA 1 Study. Diabetes Technol Ther, 2017; 19:516–526.
2.
KapitzaC, NowotnyI, LehmannA, et al.: Similar pharmacokinetics and pharmacodynamics of rapid-acting insulin lispro products SAR342434 and US- and EU-approved Humalog in subjects with type 1 diabetes. Diabetes Obes Metab, 2017; 19:622–627.
3.
HeinemannL, FritzI, KhatamiH, EdelmanSV: Administration of biosimilar insulin analogs: role of devices. Diabetes Technol Ther, 2017; 19:79–84.
4.
CarterAW, HeinemannL: If PBMs guard access to drugs, then Quis Custodiet Ipsos Custodies? (Who will guard the guardians?). J Diabetes Sci Technol, 2016; 10:1406–1410.
5.
HeinemannL: Biosimilar insulin and costs: what can we expect?. J Diabetes Sci Technol, 2015; 10:457–462.
6.
CarterAW, HeinemannL, KlonoffDC: Quality control of insulins and biosimilar insulins: what do we know?. J Diabetes Sci Technol, 2016; 10:811–815.
7.
JohnsonC: The generic drug industry has brought huge cost savings. That may be changing. Washington Post (8/1/17) www.washingtonpost.com/business/economy/the-generic-drug-industry-has-brought-huge-cost-savings-that-may-be-changing/2017/08/01/ee128d0a-68cf-11e7-8eb5-cbccc2e7bfbf_story.html?utm_term=.530be40683e5 (accessed August1, 2017).
